Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 19/20 | 0.60 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.59 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468531 | 1.00 | CCR5 (0.60) | CCR5CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL13920773 | 1.00 | CCR5 (0.60) | CCR5CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4457646 | 0.89 | CCR5 (0.58) | CCR5 | |
| SCHEMBL4457645 | 0.89 | CCR5 (0.58) | CCR5 | |
| SCHEMBL5471749 | 0.86 | CACNA2D1 (0.56) | CCR5CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL5471741 | 0.86 | CACNA2D1 (0.56) | CCR5CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4461948 | 0.82 | CCR5 (0.60) | CCR5 | |
| SCHEMBL4461952 | 0.82 | CCR5 (0.60) | CCR5 | |
| SCHEMBL13920772 | 0.82 | CCR5 (0.61) | CCR5 | |
| SCHEMBL4457628 | 0.77 | CCR5 (0.56) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165065-A1 | N-type calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2005-07-28 | — | — | US | claimed |
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | disclosed |
| US-20050165065-A1 | N-type calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165065-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | CCR5 3482/4885CACNA2D1 40/4885CACNA1B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.